Clinical Data Lilly debuts more Foundayo data as FDA requests post-marketing trials Pharmaceutical TechnologyThe FDA requires Eli Lilly to evaluate "unexpected serious" risks associated with Foundayo - some of which have been addressed by the ACHIEVE-4 trial.Clinical DataMetabolic & GLP-1Read full story pharminent April 16, 2026 (Last updated: April 16, 2026) Pharmaceutical Technology The FDA requires Eli Lilly to evaluate “unexpected serious” risks associated with Foundayo – some of which have been addressed by the ACHIEVE-4 trial. Clinical DataMetabolic & GLP-1Read full story Post navigation Previous: Roche to start new Elevidys study following setback in EuropeNext: Lilly’s new obesity pill passes heart safety test in diabetes Related Stories Clinical Data Novo Nordisk starts trialing lower maintenance doses of oral Wegovy pharminent August 21, 2026 Clinical Data Cancer vaccine win restores Wall Street’s faith in Moderna pharminent August 20, 2026 Clinical Data New Taiho, Cullian data heats up lung cancer drug battle pharminent August 13, 2026
